Navigation Links
Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
Date:1/29/2013

s, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

About Keryx Biopharmaceuticals, Inc. 

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease.  Keryx is headquartered in New York City. 

KERYX CONTACT: 
Lauren Fischer 
Director - Investor Relations 
Keryx Biopharmaceuticals, Inc. 
Tel: 212.531.5965 
E-mail: lfischer@keryx.com 

 

 


'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
6. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
7. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
8. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
9. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
10. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
11. Generex Announces Details of Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... S.C. , April 23, 2015 Once ... and strengthening our commitment to patient safety. ... the fight against infectious disease. The next ... Medical gas sensors are now mounted in the ... the need to open ceiling tiles potentially releasing dust ...
(Date:4/23/2015)... -- Research Solutions, Inc. (OTCQB: RSSS), a pioneer in providing on-demand ... life science companies, academic institutions, and other research intensive ... th Annual B. Riley & Co. Investor Conference ... Loews Hollywood Hotel in Los Angeles ... scheduled to present on Tuesday, May 12 th ...
(Date:4/23/2015)... AUGUSTA, Ga. , April 23, 2015 /PRNewswire/ ... of medical holography, has made its Voxgram hologram ... just-launched Kickstarter campaign: https://www.kickstarter.com/projects/629071847/holographic-optical-technologies?ref=nav_search ... first consumer product through the campaign, the eight-inch ... a reward, along with its more established, medical-grade ...
Breaking Medicine Technology:BeaconMedaes launches new Zone Valve Box Assembly 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 3Holographic Optical Technologies Launches Kickstarter, Offering True 3D Holograms 2
... Nov. 12 Zimmer Holdings, Inc. (NYSE: ZMH ; ... $1.0 billion of its senior unsecured notes in an underwritten ... 2019 and $500.0 million of 5.75% notes due 2039. The ... their Treasury benchmark, and the 30-year notes were priced at ...
... new treatment for autism appears to normalize brain function, ... BCIA-EEG. , In addition to high serotonin ... pattern reflecting impaired brain function, particularly in areas of ... bonding. , However, Quantitative EEG,s conducted ...
Cached Medicine Technology:Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes 2New Treatment for Autism 'Holds Promise' 2New Treatment for Autism 'Holds Promise' 3
(Date:4/24/2015)... Eastern Star Masonic Home is hosting an Open House to ... from 1:30-3:00 pm. , Residents from Boone and the surrounding ... opening of the new community room. Light refreshments will be ... to anyone who wishes to visit the rest of the ... be available for use by residents of the facility as ...
(Date:4/24/2015)... Buffalo, New York (PRWEB) April 24, 2015 ... has partnered with Allergy and Asthma Network (The Network), ... PURE Solutions will provide news, tips and information ... on The Network’s newly redesigned website. , The goal ... raising awareness about the travel needs of people with ...
(Date:4/24/2015)... 2015 E-Factor Diet claims to be a ... stress and allows people to enjoy food as rapid weight ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... blueprint that Jared used to lose weight, and all the ... included inside. This is a diet for people who are ...
(Date:4/24/2015)... Del Mar, CA (PRWEB) April 24, 2015 ... newest addition to the staff, Jamie Johansen. She will ... practice, including human resources, patient relations, and reporting. Jamie ... spa and cosmetic surgery sector as the new Practice ... Operations at LaserAway and Practice Manager at American Laser ...
(Date:4/23/2015)... 23, 2015 Fitnet , the only ... now, an accurate calorie counter during video exercise, is featured ... Health and Fitness categories in the Apple Watch App Store ... of the Digital age," now allows clients to use it ... only third party app providing accurate calorie burn counter, cardio ...
Breaking Medicine News(10 mins):Health News:PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy Travel Tips 2Health News:E-Factor Diet: Review Examining John Rowley’s Brand New Weight Loss Program Released 2Health News:Fitnet Handpicked as Top Healthy Living App in Apple Watch Store 2Health News:Fitnet Handpicked as Top Healthy Living App in Apple Watch Store 3
... discovered a protein signaling pathway that becomes hyperactivated in human ... be effective in the treatment of human sarcomas. The ... Cancer Cell . A team of researchers led ... and Chairman of the Department of Oncological Sciences at Mount ...
... St. Louis, MO 23 May, 2011 ... and medical information products and services, announced today ... (METI), a leading manufacturer of medical simulation and ... to release a turn-key health care education product ...
... researchers, including a number from the University of North Carolina ... the genome that contribute to the debilitating lung disease that ... provide insight into the causes of the wide variation in ... the way to new diagnostic markers and therapeutic approaches for ...
... the name of an infection that causes a series of reactions ... The problem for both patients and doctors is that the early ... a severe flu or winter vomiting disease. A researcher at Lund ... which shows both whether a patient has sepsis and how serious ...
... SUNDAY, May 22 (HealthDay News) -- New Swedish research ... major cardiovascular complications among patients who have a ... builds on earlier work that was published by the ... That study suggested that Inspra (eplerenone), an aldosterone antagonist, ...
... the Florida campus of The Scripps Research Institute have for ... natural product isolated from the bark of a plant widely ... foundation to develop an effective alternative to commonly prescribed narcotic ... in an advanced online edition of the journal Nature ...
Cached Medicine News:Health News:Mount Sinai researchers discover possible new target for sarcoma treatment and prevention 2Health News:Elsevier and METI collaborate to offer simulation technology for health science curriculums 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Quicker detection and treatment of severe sepsis 2Health News:Blood Pressure Drug Helps Those With Mild Heart Failure 2Health News:Led by advances in chemical synthesis, scientists find natural product shows pain-killing properties 2Health News:Led by advances in chemical synthesis, scientists find natural product shows pain-killing properties 3
... a foldable silicone IOL. It features a ... designed to be inserted with The UNFOLDER® ... is the first and only FDA-approved multifocal ... a full range of functional visionnear, intermediate, ...
... with optimum molecular weight and viscosity, so ... coats and protects the delicate structures of ... balance of cohesion, adhesion, and pseudoplasticity to ... phaco surgeon expects from an ophthalmic viscoelastic ...
... Healon GV is a sterile, non-pyrogenic, ... purified, noninflammatory, high molecular weight (average ... sodium hyaluronate. Healon GV contains 14 ... in a physiological sodium chloride-phosphate buffer ...
... PROVISC ophthalmic viscosurgical device is ... characterized by high molecular weight, ... tension. It provides excellent space ... is easily removed. It is ...
Medicine Products: